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Haptoglobin study in MyastHenia gravis
Leonardo H. Mendonça Oliveira1a, Marcondes C. França Jr1b, Anamarli Nucci1c, 
Denise Madureira de Oliveira 2a, Elza Myiuki Kimura 2a, Maria de Fátima Sonati2b
Abstract – Objective: A cross-sectional study of haptoglobin (Hp) in myasthenia gravis (MG) was designed, with 
the objective to identify its values and correlate them with different disease status.  Method: 46 patients were 
enrolled in the study, all having disease severity established according to the quantitative myasthenia gravis 
strength scores (QMGSS). Based on the functional scale determined by Myasthenia Gravis Foundation of 
America (MGFA) recommendations, patients were classified as having: complete stable remission (CSR; n=10); 
minimal manifestations–0 (MM0; n=6), minimal manifestations–1 (MM1; n=4); pharmacological remission (PR; 
n=6). Two other groups participated: thymomatous patients (T; n=10) and patients without imunosuppression or 
thymectomy, until the assessment for Hp (WIT; n=10). Hp dosage was done by immunonephelometry, blindly to 
clinical data. Student´s t-test, Anova test and linear regression were employed for statistical analyses.  Results: 
Statistically significant differences occurred between CSR+MM0xWIT groups (86.62x157.57, p<0.001) and 
PR+MM1xWIT groups (73.93x157.57, p<0.001). Linear regression showed correlation between Hp levels and 
QMGSS (r=0.759, p<0.001).  Conclusion: Our results suggest that Hp may be useful in clinical practice as a 
disease severity marker in MG. 
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estudo sobre a haptoglobina na miastenia grave
Resumo – Objectivo: Desenhou-se estudo transversal sobre a haptoglobina (Hp) na miastenia grave (MG) com o 
objetivo de identificar seus valores e correlacioná-los a diferentes condições na doença.  Método: 46 pacientes 
foram incluídos, todos tendo a gravidade da doença estabelecida segundo escores internacionais (QMGSS). 
Os pacientes tiveram seu estado funcional determinado de acordo com a Myasthenia Gravis Foundation of 
América (MGFA) e classificados em: remissão completa estável (CSR; n=10); mínima manifestação–0 (MM0; 
n=6), mínima manifestação–1 (MM1; n=4); remissão farmacológica (PR; n=6). Dois outros grupos participaram: 
pacientes timomatosos (T; n=10) e pacientes sem imunossupressão ou timectomia, até o momento da inclusão 
no estudo (WIT; n=10). A dosagem de Hp foi realizada por imunonefelometria, de modo cego quanto à clínica. As 
análises estatísticas incluíram o teste de Student, Anova e regressão linear.  Resultados: Observou-se diferença 
significativa entre os grupos CSR+MM0xWIT (86,62x157,57, p<0,001) e entre PR+MM1xWIT (73,93x157,57, 
p<0,001). A regressão linear mostrou correlação positiva entre os valores de Hp e os escores QMGSS (r=0,759, 
p<0,001).  Conclusão: O estudo sugere que valores altos de Hp se correlacionaram a maior gravidade da MG. 
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Haptoglobin (Hp) is an acute phase inflammatory a2-
glicoprotein synthesized in the liver1,2. It binds free hemo-
globin in the plasma and thereby inhibits its oxidative ac-
tivity in other tissues1-3. In the immune system, Hp mod-
ulates the function of T helper lymphocytes and inhibits 
the CD22 binding to activated TNF-a3. Due to polymor-
phisms in the gene encoding Hp on chromosome 16q22, 
there are three distinct human Hp phenotypes: Hp 1-1, Hp 
2-1 and Hp 2-21,3,4. Hp has been used as a diagnostic and 
prognostic marker in several neurological and non-neuro-
logical conditions1. Hp 1-1 phenotype has been associated 
with better seizure control in some epileptic syndromes5,6. 
A decreased risk of vasospasm after aneurismal subarach-
noid hemorrhage has been associated with Hp 1-17. In Guil-
lain-Barré syndrome (GBS) high levels of serum Hp were 
identified and attributed to the concomitant raise in Inter-
leukin 6 (IL 6)8. More recently, elevation of Hp levels in the 





Myasthenia gravis (MG) is the most frequent disor-
der of the neuromuscular junction and is characterized 
by fluctuating weakness either restricted to extrinsic oc-
ular muscles or expressed in a more generalized distribu-
tion10,11. It is an autoimmune disease caused by antibodies 
against acetylcholine receptors (Ab-AChR) in about 95% 
of cases, and may be associated with other autoimmune 
diseases10. T lymphocytes and proinflammatory cytokines 
play key roles in the pathogenesis of MG10,12. Thymus is in-
volved in the disease process since thymic hyperplasia oc-
curs in 60% of MG cases and thymoma in 15%10,11. 
As MG shares some pathogenic features with auto-
immune diseases, such as GBS8,10, in which Hp was proven 
useful, we investigated Hp values in MG patients looking 
for its possible utility as a marker of disease activity. 
MetHod
This study was approved by the Ethics Committee of Faculty 
of Medical Sciences, Clinical Hospital, Campinas State Universi-
ty. A written informed consent was obtained from all patients. 
Study design
In a cohort of prospectively selected MG patients, we per-
formed a cross-sectional study of Hp values. 
Subjects selection
Adult patients fulfilling clinical and laboratorial criteria for 
MG and attending the Neuromuscular outpatient clinic were 
enrolled in the study. Quantitative myasthenia gravis strength 
score (QMGSS)13 was employed to assess disease severity. Pa-
tient’s functional status was determined in accordance to Myas-
thenia Gravis Foundation of America (MGFA) recommendations13 
and divided into four functional groups: 1) Complete stable re-
mission (CSR): no symptoms or signs of MG (clinical score=0) for 
at least one year and without immunosuppressive therapy during 
that time; 2) Minimal manifestations – 0 (MM0): no symptoms 
or functional limitations due to MG, but patient had weakness 
of some muscles upon examination (clinical score=1) without 
immunosuppressive therapy for at least one year; 3) Pharma-
cologic remission (PR), the same criteria as for CSR, except that 
patient continued to take immunosuppressive therapy; 4) Mini-
mal manifestations – 1 (MM1), the same criteria as for MM-0, ex-
cept that patient continued to take immunosuppressive thera-
py. Two other groups of patients were included, also evaluated 
by QMGSS: 5) Thymomatous (T) patients with histopathological 
diagnosis, regardless of symptoms or treatment in the moment 
of the study; 6) MG symptomatic patients (QMGSS>1) without 
immunosuppression or thymectomy (WIT). Patients in the WIT 
group were referred to our institution, eventually using anticho-
linesterasic drugs, and they were submitted to immunosuppres-
sive treatment after venous puncture for Hp study. 
Haptoglobin dosage
Blood samples from each patient were collected and the Hp 
concentration was determined by immunonephelometry (Dade 
Behring, Marbung, Germany), blindly to the classification of pa-
tients in the study. 
Statistical analyses
Differences between two groups were compared by Stu-
dent’s t-test. Comparison of Hp levels in multiple groups was 
accomplished by the Anova test and Tukey´s post-hoc analysis. 
We employed linear regression to analyze correlations between 
Hp levels and QMGSS. MG patients with other active immune-
mediated co-morbidity were excluded from final analysis. Anal-
yses were performed on SYSTAT 10.2 software and the level of 
significance was assumed at p<0.05.
results
Forty-six patients participated in the study, 27 women 
and 19 men. Mean age was 41.7 years (range 18 to 76 years) 
and the mean duration of disease was 7.1 years. There were 
10 patients in the CSR group, 6 in MM-0, 6 in PR, 4 in 
MM-1, 10 in T and 10 in WIT group. For statistical analyses, 
groups CSR and MM0 were fused into final fCSR group. 
Similarly, groups PR and MM1 were fused into final fPR 
group. Clinical and laboratorial data of patients on group 
fCSR, fPR, T and WIT are displayed on Tables 1 to 4. 
In Tables 1 and 2 we can observe three patients with 
active autoimmune co-morbidities, indicated by clinical 
history through chart revision, previous specialized clin-
ical and laboratory follow-up and specific treatment in 
course. They were cases 7 and 13 in the group CSR and 
case 22 in the group PR; their Hp values were the highest 
Fig 1. Box-and-whiskers plot showing Hp levels in the different groups 
of MG patients. The box extends from the 25th percentile to the 75th 
percentile, with a horizontal line at the median (50th percentile). 





in each respective group so these patients were excluded 
from final analysis to avoid a statistical bias.
Figure 1 shows Hp levels in the different groups of 
MG patients. The mean Hp value in fCSR, fPR, WIT and T 
groups were 86.62, 73.93, 157.57 and 126.39 mg/dL, respec-
tively. Comparing Hp values in these different groups (Fig 
1), we found statistically significant differences only be-
tween groups fCSRxWIT (86.62x157.57, p<0.001) and be-
tween groups fPRxWIT (73.93x157.57, p<0.001). 
We hypothesized that Hp levels correlated with dis-
ease severity in MG patients and performed two addi-
tional analyses. First, we compared Hp in symptomatic 
(QMGSS>1) versus asymptomatic (QMGSS≤1) patients (re-
gardless of medication status) and found significantly low-
er results in the latter group (154.1x95.5, p<0.001 – Fig 2). 
Second, we used linear regression analyses that showed 
a significant correlation between Hp levels and QMGSS 
(r=0.759, p<0.001 – Fig 3).
Fig 2. Box-and-whiskers plot showing Hp levels in asymptomatic 
(QMGSS≤1) and symptomatic (QMGSS>1) MG patients. The box ex-
tends from the 25th percentile to the 75th percentile, with a horizon-
tal line at the median (50th percentile). Whiskers extend down to the 
smallest value and up to the largest.
Fig 3. Linear regression analysis of Hp values and QMGSS in MG 
patients.
Table 1. Hp levels on fCSR (CSR+MM1) group.












1 F 26 / 34 No Yes Involution No 00 75.3
2 F 30 / 42 No Yes  Hyperplasia No 00 95.9
3 F 21 / 31 No Yes Hyperplasia No 00 40.9
4 F 40 / 64 No Yes Normal No 00 73.3
5 F 39 / 59 No Yes Hyperplasia No 00 55.3
6 F 15 / 22 No Yes Hyperplasia No 00 78.3
7 F 32 / 53 Hashimoto* No – No 00 160.0
8 F 19 / 28 No Yes Hyperplasia No 00 110.0
9 M 23 / 36 Hashimoto# Yes Hyperplasia No 00 92.8
10 M 28 / 35 No No – No 00 119.0
11 F 14 / 25 No Yes Hyperplasia No 01 89.7
12 F 28 / 39 No Yes Normal No 01 59.2
13 F 27 / 33 IUR* Yes Hypertrofia No 01 211.0
14 M 22 / 27 No Yes Hyperplasia No 01 99.0
15 F 32 / 39 No Yes Hyperplasia No 01 123.0
16 M 50 / 62 No Yes Atrophy No 01 101.0
F, female; M, male; Ao, age of disease onset; As, age at study; *active illness; #illness in remission; IUR, inflammatory ulcerative 





Table 2. Hp levels on fPR (PR+MM1) group.












17 M 20 / 23 No No – Aza / Pred 00 139.0
18 F 61 / 66 No No – Pred 00 83.8
19 M 62 / 68 No No – Aza 00 72.5
20 M 64 / 72 No No – Aza 00 63.7
21 F 18 / 22 No No – Aza 00 26.7
22 M 27 / 35 Pemphigus Yes Hyperplasia Aza / Pred 00 187.0
23 M 33 / 44 IUR# Yes Atrophy Pred 01 63.4
24 F 48 / 51 No No – Aza 01 49.2
25 F 32 / 34 No No – Aza / Pred 01 96.0
26 M 24 / 26 No No – Aza 01 71.1
F, female; M, male; Ao, age of disease onset; As, age at study;*active illness; #illness in remission; IUR, inflammatory ulcerative 
rectocolitis; Aza, azatioprine; Pred, prednisone.
Table 3. Hp levels on T group.












27 M 44 / 55 No Yes Lymphoepithelial T No 05 126.0
28 F 52 / 57 No Yes Invasive T No 04 133.0
29 F 46 / 56 No Yes No invasive T Aza 00 109.0
30 F 32 / 46 No Yes Multifocus T No 00 82.1
31 M 17 / 25 No Yes Invasive T Aza 10 130.0
32 M 33 / 37 No Yes Invasive T Pred 10 155.0
33 M 26 / 39 No Yes No invasive T Aza 00 131.0
34 M 19 / 22 No Yes Invasive T Aza 10 193.0
35 M 33 / 37 No Yes Lymphoepithelial T Pred 00 155.0
36 F 26 / 37 No Yes Microthymoma No 00 49.8
F, female; M, male; Ao, age of disease onset; As, age at study; Aza, azatioprine; Pred, prednisone; T, thymoma.
discussion
To our knowledge, this is the first study of Hp val-
ues in patients with MG. We found that groups fCSR and 
fPR presented lower Hp levels when compared to WIT 
group, composed of MG patients in their natural disease 
state, eventually taking symptomatic drugs, but without 
effective treatment. Similarly, symptomatic patients had 
higher Hp levels in comparison to asymptomatic patients. 
Group T did not present significantly different Hp levels 
in comparison to other groups. This is possibly explained 
by the clinical heterogeneity of the group, which includes 
five patients in remission and five patients with active dis-
ease. Further, there was a positive correlation between 
Hp levels and QMGSS among symptomatic MG individ-
uals. Overall, these findings indicate that active disease 
(QMGSS>1) is associated with raised Hp levels, regardless 
of thymus status or medication in use.
The production of Ab-AChR is mediated by cytokines 
produced by CD4+ and CD8+ T helper (Th) cells12. IL-4, IL-6 
and IL-10, all Th2 cytokines, are an efficient growth pro-
moter for B-cell proliferation and differentiation, acting 
mainly in disease progression and persistence12. Interferon-
γ, a Th1 cytokine, is important in inducing B-cell maturation, 
acting more agile at the onset of MG, probably being one 
of the initiating factors in the induction of the disease12. In 
contrast, transforming growth factor- β (TGF-β) and IFN-
a exerts immunosuppressive effects, which include the 
down regulation of both Th1 and Th2 cytokines in MG12.
Hp is an acute phase protein that binds free hemoglo-
bin and removes it from the circulation to prevent kidney 
injury and iron loss following hemolysis, thus having an 
important antioxidant action2,3. In addition, Hp acts as a 
potent immunosuppressor of lymphocyte function and 
modulates the Th1 and Th2 balance within the body1,3. It 
also binds to human B-cell by the CD22 surface receptor 
and is involved in immune and inflammatory responses3. 
CD22 mediates B-cell interactions with erythrocytes, T 





ing to glycoprotein3. When Hp binds to CD22 it inhibits 
the TNF-a-activated action3. TNF-a is a proinflammatory 
cytokine implicated in MG pathogenesis14,15. The soluble 
recombinant TNF receptor Fc protein, etanercept, has 
been tested in MG patients showing benefit in those with 
low plasma IL-6 levels14. 
The high serum Hp levels observed in the study are 
consistent with an active inflammatory state in MG pa-
tients1,3. Hp is closely related to IL-6, which is the main 
stimulatory cytokine responsible for its production in 
the liver1,3. Interestingly, IL-6 acts in MG as an important 
growth and differentiation factor of B lymphocytes, which 
are directly related to the damage in the mioneural plate12. 
Moreover, lower IL-6 levels have been associated with bet-
ter therapeutic results in MG patients treated with etan-
ercept14. It is thus expected that in cases of active disease, 
there is aggression to the mioneural plate and therefore, 
high levels of IL-6. So, indirectly there would be raised 
Hp values. This reasoning could also explain the relation 
between the clinical score and Hp levels, since more in-
tense inflammatory process may be associated with more 
prominent symptoms11. Similarly, there are elevated serum 
Hp levels in GBS patients, which have been explained by 
the concomitant increase of IL-6 levels8.
Hp values are not disease-specific, explaining that pa-
tients in clinical remission of MG, but presenting another 
active autoimmune illness had high values of Hp than MG 
patients without active autoimmune comorbidity. In these 
cases, Hp would reflect the activity of disease comorbid-
ity, not that of MG. According to Christensen et al.16, 14% 
of MG patients presented concomitant autoimmune dis-
ease, therefore clinicians must be alert to evaluate each 
autoimmune illness independently, and consider Hp val-
ues in a contextual setting. 
In conclusion, we suggest that Hp can be useful as a marker 
of clinical activity in MG without another associated illness.
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Table 4. Hp levels on WIT group. 










37 F 34 / 50 No No No 03      153.0
38 M 73 / 76 No No No 08 194.0
39 F 32 / 34 No No No 09 98.5
40 F 27 / 30 No No No 08 107.0
41 M 48 / 48 No No No 06 66.2
42 M 66 / 66 No No No 09 178.0
43 F 31 / 32 No No No 22 221.0
44 F 17 / 18 No No No 14 189.0
45 M 50 / 60 No No No 08 202.0
46 F 22 / 23 No No No 10 167.0
F, female; M, male; Ao, age of disease onset; As, age at study.
